An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers. (PREPA-10)
An Observational Study of the Prevalence of Patients Requiring Palliative Care in the French Anti Cancer Centers.
The purpose of this observational study is to determine the proportion of patients with a score greater than 3/10 to the questionnaire PALLIA-10.
This questionnaire is a tool provided by the French Society for Palliative Cares, aiming at helping the providers of care to identify patients who would require palliative cares.
According to the notice of the questionnaire, patients with a score greater than 3 would be taken in charge by a palliative care team. Considerong the 10 itmes of this questionnaire, it seems that a large majority of patients would have a score greater than 3 in the context of anti cancer centers.
To date, palliative teams are not designed to take in charge such an amount of patients.
調査の概要
詳細な説明
Continuous improvement of therapeutics helped to lengthen different stages of natural cancer evolution. Advanced cancer patients are followed-up even longer; therefore there is a need to increase palliative care resources. A global therapeutic approach is being set up gradually thanks to specialized supportive care team. This global approach includes therapeutics and life condition improvement of the patient and his family.
In France, only 2 anti-cancer centers have a palliative care unit. The 16 other centers design hospital beds for palliative care and work with mobile palliative care teams.
According to latest studies with high level of evidence, International oncology societies published good practices guidelines supporting the need of early palliative cares for patients with metastatic cancer.
In 2010, Temel et al. demonstrated early palliative care effectiveness. Indeed, early palliative care led to significant improvements in both quality of life (score on the FACT-L scale: 98.0 vs. 91.5; p=0.03) and mood (depressive symptoms: 16% vs. 38%, P=0.01). Moreover median survival was longer among patients receiving early palliative care (11.6 months vs. 8.9 months, p=0.02). Analysis showed that patients assigned to early palliative care stopped chemotherapy earlier, had a higher enrollment rate in palliative care units and less depressive symptoms when cares were provided by both oncologists and palliative care teams.
Other specific scales support efficiency of early palliative care on quality of life. Early palliative care increases also satisfaction of the cares. Therefore, these results illustrate the need for an early integration of palliative care in France; and this approach is recommended in the third national plan against cancer.
Despite efficacy data, no high international consensus exists on a screening score for patients requiring early palliative care. Some teams therefore use prognostic factors like Barbot score.
Confronted with such difficulties, the French Society for Counselling and Palliative Care create a score (PALLIA-10) with 10 items on personal situation of the patient and his disease. This score helps medical staffs to direct patients to a specialized team as soon as it is > 3/10.
PALLI-10 score is not optimized because of the large number of patients with a score > 3 in the French anti-cancer centers. In 2014, a team from Centre Fraçois Baclesse (Caen, France) showed that nearly 65% of hospitalized patients in medicine department has a score PALLIA-10 > 3/10. Today, mobile palliative care teams are too small to manage so many patients.
First, it is important to evaluate the prevalence of these patients in France. Description of patients hospitalized in a Center for the Treatment of Cancers should help us to describe the characteristics of patients requiring cares provided by a mobile palliative care team.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Angers、フランス、49933
- Institut de cancérologie de l'ouest
-
Bordeaux、フランス、33076
- Institut Bergonié
-
Caen、フランス、14000
- Centre Francois Baclesse
-
Clermont Ferrand、フランス、63011
- Centre Jean Perrin
-
Lille、フランス、59020
- Centre Oscar Lambret
-
Lyon、フランス、69008
- Centre Leon Berard
-
Marseille、フランス、13009
- Institut Paoli Calmettes
-
Montpellier、フランス、34298
- Institut Régional du Cancer de Montpellier
-
Nice、フランス、06189
- Centre Antoine Lacassagne
-
Paris - Saint Cloud、フランス、75005
- Institut Curie
-
Reims、フランス、51726
- Institut Jean Godinot
-
Rennes、フランス、35000
- Centre Eugene Marquis
-
Strasbourg、フランス、67085
- Centre Paul Strauss
-
Toulouse、フランス、31059
- Institut Universitaire du Cancer de Toulouse Oncopole
-
Vandoeuvre-lès-Nancy、フランス、54519
- Institut de Cancerologie de Lorraine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- 18-year old or older
- Hospitalized in a conventionnal medical service, including radiotherapy, brachytherapy, palliative care units.
Exclusion Criteria:
- Patient hospitalized in an out-patient service, surgery unit, weekly units
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Proportion of patients with a score greater than 3/10 to questionnaire PALLIA-10 in the population of patients hospitalized in a French cancer center.
時間枠：Day 1 of the study
|
Day 1 of the study
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
The proportion of patients with a score greater than 5 to questionnaire PALLIA-10
時間枠：Day 1 of the study
|
Day 1 of the study
|
|
Proportion of patients already followed-up by a palliative care team
時間枠：Day 1 of the study
|
Day 1 of the study
|
|
Mean score to questionnaire PALLIA-10
時間枠：Day 1 of the study
|
Day 1 of the study
|
|
Predictive factors of current palliative cares
時間枠：Day 1 of the study
|
Day 1 of the study
|
|
Prognostic factors of overall survival
時間枠：From Day 1 of the study to the update of survival status (6 months later)
|
From Day 1 of the study to the update of survival status (6 months later)
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Gisèle CHVETZOFF, MD、Centre Leon Berard
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。